Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-FU on human carcinoma cells

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 2927-2932

  Wang, Chong Zhi ^a,b   Li, Xiao Li ^a,b   Sun, Shi ^a,b   Xie, Jing Tian ^a,b   Aung, Han H ^a,b   Tong, Robin ^a,b   Mcentee, Eryn ^a,b   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 fluorouracil; Anti proliferation; Cell cycle; Cell growth; MCF 7 breast cancer cell; Methylnaltrexone; Non small cell lung cancer cell; NSCLC; SW 480 colorectal cancer cell

Indexed keywords

17 METHYLNALTREXONE; ANTINEOPLASTIC AGENT; CYCLIN A; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; OPIATE ANTAGONIST; PROPIDIUM IODIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER THERAPY; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOTHERAPY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN A; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID; TUMOR CELLS, CULTURED;

EID: 68549107734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Walsh TD: Oral morphine in chronic cancer pain. Pain 18: 1-11, 1984. (Pubitemid 14219536)
2. Yap Y and Pappagallo M: The epidemiology of opioid bowel dysfunction. In: Handbook of Opioid Bowel Syndrome. Chun-Su Yuan (eds.). New York, NY, Haworth Medical Press, pp. 61-67, 2005.
3. Glare P and Lickiss JN: Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 7: 369-371, 1992.
4. Walsh TD: Prevention of opioid side effects. J Pain Symptom Manage 5: 362-367, 1990.
5. Yuan CS, Foss JF, O'Connor M, Moss J and Roizen MF: Gut motility and transit changes in patients receiving long-term methadone maintenance. J Clin Pharmacol 38: 931-935, 1998. (Pubitemid 28482119)
6. Whitecar PS, Jonas AP and Clasen ME: Managing pain in the dying patient. Am Fam Physician 61: 755-764, 2000.
7. Fallon MT and Hanks GW: Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13: 159-160, 1999. (Pubitemid 29171397)
8. Klepstad P, Kaasa S, Skauge M and Borchgrevink PC: Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 44: 656-664, 2000. (Pubitemid 30413411)
9. Mercadante S, Fulfaro F and Casuccio A: The impact of home palliative care on symptoms in advanced cancer patients. Support Care Cancer 8: 307-310, 2000. (Pubitemid 30430054)
10. Sykes NP: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12: 375-382, 1998. (Pubitemid 28454405)
11. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J and Roizen MF: Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283: 367-372, 2000. (Pubitemid 30051755)
12. Yuan CS and Israel RJ: Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 15: 541-552, 2006.
13. Brown DR and Goldberg LI: The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24: 181-191, 1985.
14. Woods JH, Medzihradsky F, Smith CB, Young AM and Swain HH: Annual report: evaluation of new compounds for opioid activity (1980). NIDA Res Monogr 34: 327-366, 1981.
15. Russell J, Bass P, Goldberg LI, Schuster CR and Merz H: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78: 255-261, 1982. (Pubitemid 12190685)
16. Yuan CS: Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. J Support Oncol 2: 111-117; discussion 119-122, 2004.
17. Guo HY, Cai Y, Yang XM, Wang ZH, Wang JL, Zhao XM, Li J and Hu XC: Randomized phase II trial on mitomycin-C/cisplatin +- KLT in heavily pretreated advanced breast cancer. Am J Chin Med 36: 665-674, 2008.
18. Wang CZ, Aung HH, Zhang B, Sun S, Li XL, He H, Xie JT, He TC, Du W and Yuan CS: Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells. Anticancer Res 28: 2545-2551, 2008.
19. Cheng YL, Lee SC, Harn HJ, Huang HC and Chang WL: The extract of Hibiscus syriacus inducing apoptosis by activating p53 and AIF in human lung cancer cells. Am J Chin Med 36: 171-184, 2008.
20. Wang CZ and Yuan CS: Potential role of ginseng in the treatment of colorectal cancer. Am J Chin Med 36: 1019-1028, 2008.
21. Garmanchouk LV, Pyaskovskaya ON, Yanish YV, Shlyakhovenko VA, Dasyukevich OI and Solyanik GI: Influence of aconitine-containing herbal extract BC1 on proliferative and electrokinetic characteristics of endothelial cells. Exp Oncol 27: 262-266, 2005.
22. Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC and Yuan CS: Notoginseng enhances anticancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60: 69-79, 2007. (Pubitemid 46643720)
23. Wang CZ, Xie JT, Zhang B, Ni M, Fishbein A, Aung HH, Mehendale SR, Du W, He TC and Yuan CS: Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol 31: 1149-1156, 2007.
24. Reed JC and Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood 106: 408-418, 2005.
25. Caballero-Hernandez D, Weber RJ, Hicks ME, Tamez-Guerra R, Rodriguez-Padilla C, Tamez-Guerra P, Rice KC, Ananthan S and Gomez-Flores R: Potentiation of rat lymphocyte proliferation by novel non-peptidic synthetic opioids. Int Immunopharmacol 5: 1271-1278, 2005. (Pubitemid 40725720)
26. Zagon IS and McLaughlin PJ: Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37: 79-88, 2003. (Pubitemid 37421490)
27. Zagon IS and McLaughlin PJ: Opioids and differentiation in human cancer cells. Neuropeptides 39: 495-505, 2005. (Pubitemid 41443526)
28. Shi P, Huang Z and Chen G: Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am J Chin Med 36: 805-813, 2008.
29. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
30. Tokunaga E, Oda S, Fukushima M, Maehara Y and Sugimachi K: Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur J Cancer 36: 1998-2006, 2000.
31. Park JK, Lee SH, Kang JH, Nishio K, Saijo N and Kuh HJ: Synergistic interaction between gefitinib (Iressa™, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 15: 809-818, 2004. (Pubitemid 39281306)
32. Shang D, Ito N, Watanabe J, Awakura Y, Nishiyama H, Kamoto T and Ogawa O: Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity. Eur Urol 52: 1131-1139, 2007. (Pubitemid 47332020)
33. Dhanabal M, Jeffers M and Larochelle WJ: Anti-angiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 5: 115-130, 2005. (Pubitemid 40347985)
34. Isayeva T, Kumar S and Ponnazhagan S: Anti-angiogenic gene therapy for cancer (review). Int J Oncol 25: 335-343, 2004.
35. Singleton PA, Lingen MW, Fekete MJ, Garcia JG and Moss J: Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 72: 3-11, 2006.
36. Singleton PA, Garcia JG and Moss J: Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 7: 1669-1679, 2008.